Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Status:
Suspended
Trial end date:
2025-08-28
Target enrollment:
Participant gender:
Summary
This research study is studying two immunotherapy drugs as a possible treatment for advanced
non-small cell lung cancer (NSCLC).
The drugs involved in this study are:
- Ipilimumab
- Nivolumab